Home › Research › Tau biomarkers
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Babić M, Svob Štrac D, Mück-Šeler D, Pivac N, Stanić G, Hof PR, Simić G.. Croatian medical journal, 2014-08-01
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically rise by 2050. Despite numerous clinical trials investigating this disease, there is still no effective treatment. Many trials showed negative or inconclusive results, possibly because they recruited only patients with severe disease, who had not undergone disease-modifying therapies in preclinical stages of AD before severe degeneration occurred.
Key findings
- Despite numerous clinical trials investigating this disease, there is still no effective treatment.
- Many trials showed negative or inconclusive results, possibly because they recruited only patients with severe disease, who had not undergone disease-modifying therapies in preclinical stages of AD before severe degeneration occurred.
- Detection of AD in asymptomatic at risk individuals (and a few presymptomatic individuals who carry an autosomal dominant monogenic AD mutation) remains impractical in many of clinical situations and is possible only with reliable biomarkers.
- In addition to early diagnosis of AD, biomarkers should serve for monitoring disease progression and response to therapy.
Why it matters
This review notes that there is still no effective treatment for Alzheimer disease and that many trials produced negative or inconclusive results, possibly because they enrolled only patients with severe disease. It suggests that detecting and treating the disease in preclinical stages might be needed, but it reports no treatment that has been shown to work.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 39/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Croatian medical journal) |
| Journal's citation record | 0 / 4 | Croatian Medical Journal: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 45 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 2 / 6 | Cited 2.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Goran Šimić: h-index 35 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Icahn School of Medicine at Mount Sinai: institution h-index 1,331 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25165049) |
| Free to read | 2 / 2 | Free to read |
| Total | 39 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3325/cmj.2014.55.347
- PubMed: 25165049
- Original source →
- Free full text: Croatian Medical Journal →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Babić, M., Svob Štrac, D., Mück-Šeler, D., Pivac, N., Stanić, G., Hof, P. R., et al. (2014). Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croatian medical journal. https://doi.org/10.3325/cmj.2014.55.347
Vancouver
Babić M, Svob Štrac D, Mück-Šeler D, Pivac N, Stanić G, Hof PR, et al. Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croatian medical journal. 2014. doi:10.3325/cmj.2014.55.347. PMID: 25165049.
BibTeX
@article{babic2014-25165049,
author = {Babić, M. and Svob Štrac, D. and Mück-Šeler, D. and Pivac, N. and Stanić, G. and Hof, P. R. and Simić, G.},
title = {{Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease}},
journal = {Croatian medical journal},
year = {2014},
doi = {10.3325/cmj.2014.55.347},
pmid = {25165049},
url = {https://doi.org/10.3325/cmj.2014.55.347}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 57.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.